A

Allakos
D

ALLK

0.87560
USD
-0.03
(-3.25%)
Market Closed
Volume
27,830
EPS
-2
Div Yield
-
P/E
-0
Market Cap
78,229,286
Related Instruments
    A
    ALKS
    -0.150
    (-0.53%)
    28.200 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    More
News

Title: Allakos

Sector: Healthcare
Industry: Biotechnology
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.